Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. (2024)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.23.00339
PubMed Identifier: 37963304
Publication URI: http://europepmc.org/abstract/MED/37963304
Type: Journal Article/Review
Volume: 42
Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue: 5
ISSN: 0732-183X